- Company
- In the aftermath of the COVID-19, the BA test was disrupted
- by Chon, Seung-Hyun Mar 4, 2020 06:27am
- COVID-19 infections have also influenced the generic development strategies of pharmaceutical companies. Due to the risk of infection with COVID-19, the bioequivalence task of medical institutions has been disrupted. This is an embarrassing situation for pharmaceutical companies that are conducting bioequivalence tests to reduce drug prices a
- Company
- Eisai’s low-dose Pariet passed by general hospital DCs
- by Eo, Yun-Ho Mar 3, 2020 06:10am
- Low-dose Pariet is landing on general hospital prescription code. Pharmaceutical industry source reported Drug Committees in Severance Hospital, Samsung Medical Center, and Korea University Guro Hospital cleared proton pump inhibitor (PPI) Pariet 5 mg tablet (rabeprazole sodium), which received National Health Insurance reimbursement in
- Company
- GSK speeds up development of COVID-19 vaccine
- by Eo, Yun-Ho Mar 2, 2020 06:22am
- GSK is focusing its capabilities on developing the COVID-19 vaccine GSK recently announced cooperation with China's biotech company Clover, following the Coalition for Epidemic Preparedness Innovations (CEPI). Together, Clover and GSK will jointly develop a protein-based COVID-19 vaccine candidate (COVID-19 S-Trimer). GSK will provid
- Company
- Hanmi-GC sign MOU for new drug R&D partnership
- by Chon, Seung-Hyun Mar 2, 2020 06:21am
- Hanmi Pharmaceutical and GC Pharma have inked the first new drug R&D partnership deal in the history. Two companies would concentrate their R&D capacity to increase the possibility of successful development of an innovative new drug. On Feb. 27, Hanmi Pharmaceutical and GC Pharma have announced the two have signed MOU on co-developing
- Company
- Panicking with first confirmed COVID-19 in industry
- by Chon, Seung-Hyun Feb 28, 2020 06:03am
- Korean pharmaceutical industry now has a first confirmed case of the 2019 novel coronavirus, COVID-19. Working at a research laboratory without much of external interaction, the infected employee is not expected to create a severe impact. But pharmaceutical companies are reinforcing precautionary measures against disease transmission. More
- Company
- Pharmaceutical staff struggle to work from home
- by Jung, Hye-Jin Feb 27, 2020 06:35am
- In the aftermath of COVID-19, face-to-face sales activities at pharmaceutical companies have declined, and alternative sales activities are increasing online. From academic papers provided by the company to light-looking articles created by the company. Pharmaceutical officials are working hard to maintain relationships with hospital doctors.
- Company
- Obesity market surpassed ￦100 billion in 10 years
- by An, Kyung-Jin Feb 27, 2020 06:33am
- Last year, 'Saxenda', which had gained popularity through going viral with 'Gangnam injection' and 'antiobestic injection', evaluated the domestic obesity treatment market. After 3rd quarterly sales, it gained the top spot, and its market share soared to almost one-third of the entire market. In the wake of the Saxenda, the total market size
- Company
- COVID-19 closes LS Tower, GSK-Janssen to work from home
- by Jung, Hye-Jin Feb 27, 2020 06:33am
- As an office worker working at LS Yongsan Tower, located in Yongsan-gu, Seoul, was confirmed have been infected with COVID-19, pharmaceutical company offices housed at the tower told their employees to work from home. The authorities of Yongsan-gu announced on Feb. 25 the LS Yongsan Tower would be closed as an office worker working on th
- Company
- Next gen Keytruda and Tagrisso skyrocket up the market rank
- by Chon, Seung-Hyun Feb 27, 2020 06:32am
- A next generation anticancer therapy developed by a multinational pharmaceutical company has shuffled through the best-selling pharmaceuticals rank in Korea. Four years since the launch, Keytruda has generated over 100 billion won a year. Tagrisso and Opdivo also showed a steep surge in growth. Pharmaceutical market research firm IQVIA on Fe
- Company
- GSK-Pfizer JV launch in Korea put off indefinitely
- by An, Kyung-Jin Feb 26, 2020 06:18pm
- Pfizer Pharmaceutical Korea and GlaxoSmithKline Korea’s (GSK Korea) Consumer Healthcare Joint Venture launch schedule in Korea took a sharp turn unexpectedly. . Pharmaceutical industry source reported Korean offices of Pfizer and GSK have announced indefinite postponement of launching the consumer healthcare division joint venture. A
